Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization

Advances in Enzyme Regulation

Volumn 48, Issue 1, 2008, Pages 152-164

  Stavenhagen, Jeffrey B ^a   Gorlatov, Sergey ^a   Tuaillon, Nadine ^a   Rankin, Christopher T ^a   Li, Hua ^a   Burke, Stephen ^a   Huang, Ling ^a   Johnson, Syd ^a   Koenig, Scott ^a   Bonvini, Ezio ^a  

^a Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIB; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN ENGINEERING; SACCHAROMYCES CEREVISIAE; VALIDATION STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; LYMPHOMA, B-CELL; MICE; NEOPLASMS, EXPERIMENTAL; PROTEIN ENGINEERING; RECEPTORS, FC; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 51349135026     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2007.11.011     Document Type: Article

References (22)

1. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 23 (2005) 1147-1157
2. Beckett D., Kovaleva E., and Schatz P.J. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci 8 (1999) 921-929
3. Boder E.T., and Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15 (1997) 553-557
4. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1 (2001) 118-129
5. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89 (1992) 4285-4289
6. Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol 6 (2006) 343-357
7. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
8. Clarkson S.B., Kimberly R.P., Valinsky J.E., Witmer M.D., Bussel J.B., Nachman R.L., et al. Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med 164 (1986) 474-489
9. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
10. Green S.K., Karlsson M.C., Ravetch J.V., and Kerbel R.S. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 62 (2002) 6891-6900
11. Gurbaxani B.M., and Morrison S.L. Development of new models for the analysis of Fc-FcRn interactions. Mol Immunol 43 (2006) 1379-1389
12. Houghton A.N., and Scheinberg D.A. Monoclonal antibody therapies - a 'constant' threat to cancer. Nat Med 6 (2000) 373-374
13. Isaacs J.D., Clark M.R., Greenwood J., and Waldmann H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol 148 (1992) 3062-3071
14. Kieke M.C., Shusta E.V., Boder E.T., Teyton L., Wittrup K.D., and Kranz D.M. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc Natl Acad Sci U S A 96 (1999) 5651-5656
15. Rankin C.T., Veri M.C., Gorlatov S., Tuaillon N., Burke S., Huang L., et al. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 108 (2006) 2384-2391
16. Ravetch J.V., and Bolland S. IgG Fc receptors. Annu Rev Immunol 19 (2001) 275-290
17. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276 (2001) 6591-6604
18. Stavenhagen J.B., Gorlatov S., Tuaillon N., Rankin C.T., Li H., Burke S., et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity Fc receptors. Cancer Res 67 (2007) 1-10
19. Treon S.P., Hansen M., Branagan A.R., Verselis S., Emmanouilides C., Kimby E., et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 23 (2005) 474-481
20. Uchida J., Hamaguchi Y., Oliver J.A., Ravetch J.V., Poe J.C., Haas K.M., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
21. Veri M.C., Gorlatov S., Li H., Burke S., Johnson S., Stavenhagen J., et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121 (2007) 392-404
22. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947